Literature DB >> 15651759

Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons.

Carolina Scagnolari1, Elisa Vicenzi, Francesca Bellomi, Maria Giuseppina Stillitano, Debora Pinna, Guido Poli, Massimo Clementi, Ferdinando Dianzani, Guido Antonelli.   

Abstract

There is currently an urgent need to identify effective antiviral agents that will prevent and treat severe acute respiratory syndrome coronavirus (SARS-CoV) infection. In this study, we have investigated and compared the antiviral effect of different interferons (IFNs) on SARS-CoV replication in the epithelial kidney monkey Vero cell line. The results showed that SARS-CoV grown in Vero cells is moderately sensitive to IFN-beta and only weakly sensitive to IFN-alpha and IFN-gamma, in comparison to other IFN-sensitive viruses, such as those for encephalomyocarditis, vesicular stomatitis and Newcastle disease. Simultaneous incubation of Vero cells with IFN-beta and IFN-gamma indicated that they may act synergistically against SARS-CoV replication. The IFN-induced MxA protein was detected in the IFN-treated Vero cells. The data, however, suggest that the antiviral activity of IFN against SARS-CoV virus is independent of MxA expression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15651759

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  40 in total

1.  Alpha/beta interferon (IFN-alpha/beta)-independent induction of IFN-lambda1 (interleukin-29) in response to Hantaan virus infection.

Authors:  Malin Stoltz; Jonas Klingström
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

Review 2.  Advances in the possible treatment of COVID-19: A review.

Authors:  Pankaj Chibber; Syed Assim Haq; Irfan Ahmed; Nusrit Iqbal Andrabi; Gurdarshan Singh
Journal:  Eur J Pharmacol       Date:  2020-07-17       Impact factor: 4.432

Review 3.  Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus.

Authors:  Susan R Weiss; Sonia Navas-Martin
Journal:  Microbiol Mol Biol Rev       Date:  2005-12       Impact factor: 11.056

4.  Synergistic inhibition of SARS-coronavirus replication by type I and type II IFN.

Authors:  Eric C Mossel; Bruno Sainz; Robert F Garry; C J Peters
Journal:  Adv Exp Med Biol       Date:  2006       Impact factor: 2.622

Review 5.  A Scoping Insight on Potential Prophylactics, Vaccines and Therapeutic Weaponry for the Ongoing Novel Coronavirus (COVID-19) Pandemic- A Comprehensive Review.

Authors:  Priyanka Dash; Subhashree Mohapatra; Sayantan Ghosh; Bismita Nayak
Journal:  Front Pharmacol       Date:  2021-02-26       Impact factor: 5.810

Review 6.  Recent advances in antiviral effects of probiotics: potential mechanism study in prevention and treatment of SARS-CoV-2.

Authors:  Nima Montazeri-Najafabady; Kimia Kazemi; Ahmad Gholami
Journal:  Biologia (Bratisl)       Date:  2022-06-28       Impact factor: 1.653

Review 7.  Respiratory viruses other than influenza virus: impact and therapeutic advances.

Authors:  W Garrett Nichols; Angela J Peck Campbell; Michael Boeckh
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

8.  The interferon gamma gene polymorphism +874 A/T is associated with severe acute respiratory syndrome.

Authors:  Wai Po Chong; W K Eddie Ip; Gloria Hoi Wan Tso; Man Wai Ng; Wilfred Hing Sang Wong; Helen Ka Wai Law; Raymond W H Yung; Eudora Y Chow; K L Au; Eric Y T Chan; Wilina Lim; J S Malik Peiris; Yu Lung Lau
Journal:  BMC Infect Dis       Date:  2006-05-04       Impact factor: 3.090

9.  Nasopharyngeal Type-I Interferon for Immediately Available Prophylaxis Against Emerging Respiratory Viral Infections.

Authors:  Amos C Lee; Yunjin Jeong; Sumin Lee; Haewook Jang; Allen Zheng; Sunghoon Kwon; John E Repine
Journal:  Front Immunol       Date:  2021-05-19       Impact factor: 7.561

Review 10.  COVID-19 and SARS-CoV-2 Variants: Current Challenges and Health Concern.

Authors:  Md Zeyaullah; Abdullah M AlShahrani; Khursheed Muzammil; Irfan Ahmad; Shane Alam; Wajihul Hasan Khan; Razi Ahmad
Journal:  Front Genet       Date:  2021-06-15       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.